Development of Burkholderia mallei and pseudomallei vaccines
about
Mechanisms of Disease: Host-Pathogen Interactions between Burkholderia Species and Lung Epithelial CellsParticulate delivery systems for vaccination against bioterrorism agents and emerging infectious pathogensCharacterization of the Burkholderia mallei tonB Mutant and Its Potential as a Backbone Strain for Vaccine DevelopmentThe Identification and Differentiation between Burkholderia mallei and Burkholderia pseudomallei Using One Gene PyrosequencingProtection against Experimental Melioidosis with a Synthetic manno-Heptopyranose Hexasaccharide GlycoconjugateMaking vaccines "on demand": a potential solution for emerging pathogens and biodefense?A Burkholderia pseudomallei outer membrane vesicle vaccine provides protection against lethal sepsis.Protection against experimental melioidosis following immunisation with a lipopolysaccharide-protein conjugate.Melioidosis: Clinical impact and public health threat in the tropics.Production of a recombinant vaccine candidate against Burkholderia pseudomallei exploiting the bacterial N-glycosylation machinery.Burkholderia pseudomallei capsular polysaccharide conjugates provide protection against acute melioidosisOropharyngeal aspiration of Burkholderia mallei and Burkholderia pseudomallei in BALB/c mice.Protection of non-human primates against glanders with a gold nanoparticle glycoconjugate vaccine.Functional characterization and evaluation of in vitro protective efficacy of murine monoclonal antibodies BURK24 and BURK37 against Burkholderia pseudomalleiEfficacy of postexposure therapy against glanders in miceCurcumin rescues Caenorhabditis elegans from a Burkholderia pseudomallei infectionCharacterization of the murine macrophage response to infection with virulent and avirulent Burkholderia species.Distinct colicin M-like bacteriocin-immunity pairs in Burkholderia.Glycoengineered Outer Membrane Vesicles: A Novel Platform for Bacterial VaccinesBurkholderia mallei CLH001 Attenuated Vaccine Strain Is Immunogenic and Protects against Acute Respiratory Glanders.Correlates of immune protection following cutaneous immunization with an attenuated Burkholderia pseudomallei vaccine.Deciphering minimal antigenic epitopes associated with Burkholderia pseudomallei and Burkholderia mallei lipopolysaccharide O-antigens.Antibodies against In Vivo-Expressed Antigens Are Sufficient To Protect against Lethal Aerosol Infection with Burkholderia mallei and Burkholderia pseudomallei.Melioidosis and glanders modulation of the innate immune system: barriers to current and future vaccine approaches.Central nervous system melioidosis in the pediatric age group: review.Recent Advances in Burkholderia mallei and B. pseudomallei Research.The Use of Reverse Vaccinology in the Design and Construction of Nano-glycoconjugate Vaccines against Burkholderia pseudomallei.Characterization of the Burkholderia cenocepacia TonB Mutant as a Potential Live Attenuated Vaccine.Melioidosis: where do we stand in the development of an effective vaccine?Vaccines for the Prevention of Melioidosis and Glanders.Potential targets for next generation anti-microbial glycoconjugate vaccines.
P2860
Q26774483-426766C3-F4F6-4517-8DF0-9E67D5630D66Q27011190-179C049F-5846-41BE-A30E-CB2CDE4AED30Q27304432-082631D3-E78A-438F-9552-BA73118F0D75Q28828549-DEC189F8-F6B9-4CFB-9BF3-D92873E96D99Q28829950-6F9A6705-9CE8-40C0-A0A9-7E0F3EC60C3DQ30222126-307B37E2-C366-473E-B601-0E47C5E11DFEQ33601907-C1870278-6B0A-44CD-A412-24F4C64BCC98Q33661479-6A40DC3F-6A7A-4823-8298-5D01E6FE924DQ33663333-2BD5D19F-784F-4197-9F8F-6350F77B75D8Q33965527-78B2FECD-6175-4A79-9506-053B1C36E24FQ34058969-875D6D76-66DA-4B4E-B683-D084D84B36D8Q34682080-ACCFC725-841E-41EB-B3E1-7B59EA766CEBQ35007523-019D6646-0E18-40E7-BF26-9C884918785BQ35116418-EE93942A-F3F3-4239-8D45-5EFE753C5B08Q35169039-680E107E-D619-49C5-B680-CB56B715BE32Q35352320-8F50E62E-4BDB-4038-A56E-7F7540340A9EQ35834729-DEEC402D-B929-4A22-8BF7-0BBF425A8962Q36323901-A906C00F-35CD-4C7B-A2CD-96239D47FA10Q36823959-A2892864-76CE-4502-9088-B72CD247544BQ37129909-693A8973-8199-4E12-AFA8-E392B858D855Q37336008-ED06B581-6B09-4986-9311-C37226C2752DQ38287677-7C160AA3-7A45-40F9-8111-9481DC55A81AQ38784773-DF2EC16C-A509-4A97-BE18-1D02428C8762Q38890754-FA046C61-9685-4073-898F-9752E83CA102Q39268714-CA14913D-ADF9-42C1-90C7-ADC5F99B9C2BQ39970602-FB2F56CA-8EDC-455B-9363-565461506D4EQ40048191-B59DAE1B-7D26-4EAA-9B62-7938EEB7AD65Q47168921-66D7EBCB-766D-46F3-B1AA-AA5EF09E81C8Q48144660-BE6A6224-45FF-44DC-85AF-0DE7F9098D22Q49834322-6AB4DC49-71E7-4251-A5EE-5CBF0CD4FA64Q53701548-0FF7E73E-0CB7-4584-8E59-23EF005159DC
P2860
Development of Burkholderia mallei and pseudomallei vaccines
description
2013 nî lūn-bûn
@nan
2013 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մարտին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Development of Burkholderia mallei and pseudomallei vaccines
@ast
Development of Burkholderia mallei and pseudomallei vaccines
@en
Development of Burkholderia mallei and pseudomallei vaccines
@nl
type
label
Development of Burkholderia mallei and pseudomallei vaccines
@ast
Development of Burkholderia mallei and pseudomallei vaccines
@en
Development of Burkholderia mallei and pseudomallei vaccines
@nl
prefLabel
Development of Burkholderia mallei and pseudomallei vaccines
@ast
Development of Burkholderia mallei and pseudomallei vaccines
@en
Development of Burkholderia mallei and pseudomallei vaccines
@nl
P2860
P921
P3181
P356
P1476
Development of Burkholderia mallei and pseudomallei vaccines
@en
P2093
Ediane B. Silva
Steven W. Dow
P2860
P3181
P356
10.3389/FCIMB.2013.00010
P407
P5008
P577
2013-01-01T00:00:00Z
2013-03-11T00:00:00Z